The Role of Alpha 2 Macroglobulin in IgG-Aggregation and Chronic Activation of the Complement System in Patients With Chronic Lymphocytic Leukemia.


Journal

Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960

Informations de publication

Date de publication:
2020
Historique:
received: 07 09 2020
accepted: 31 12 2020
entrez: 1 3 2021
pubmed: 2 3 2021
medline: 22 6 2021
Statut: epublish

Résumé

Chronic lymphocytic leukemia (CLL) is the most common leukemia in adults in the western world. One of the treatments offered for CLL is immunotherapy. These treatments activate various cellular and biochemical mechanisms, using the complement system. Recently it was shown that the complement system in CLL patients is persistently activated at a low level through the classical pathway (CP). The mechanism of chronic CP activation involves the formation of IgG-hexamers (IgG-aggregates). According to recent studies, formation of ordered IgG-hexamers occurs on cell surfaces

Identifiants

pubmed: 33643290
doi: 10.3389/fimmu.2020.603569
pmc: PMC7905172
doi:

Substances chimiques

A2M protein, human 0
Antigens 0
Endoplasmic Reticulum Chaperone BiP 0
Heat-Shock Proteins 0
Immunoglobulin G 0
Protein Aggregates 0
alpha-Macroglobulins 0

Banques de données

Dryad
['10.5061/dryad.tmpg4f4xg']

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

603569

Informations de copyright

Copyright © 2021 Naseraldeen, Michelis, Barhoum, Chezar, Tadmor, Aviv, Shvidel, Litmanovich, Shehadeh, Stemer, Shaoul and Braester.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

J Cell Biochem. 2010 Aug 15;110(6):1299-305
pubmed: 20506407
Clin Exp Immunol. 1975 Feb;19(2):237-49
pubmed: 55322
Adv Exp Med Biol. 2014;772:229-62
pubmed: 24272362
Leukemia. 1996 Sep;10(9):1509-13
pubmed: 8751471
Biochem J. 2011 Mar 1;434(2):181-8
pubmed: 21309747
J Immunol. 2001 Apr 15;166(8):4968-72
pubmed: 11290775
Mol Immunol. 2015 Aug;66(2):164-70
pubmed: 25795308
Mol Immunol. 2002 Nov;39(7-8):383-94
pubmed: 12413689
Oxid Med Cell Longev. 2019 Jul 22;2019:5410657
pubmed: 31428227
Science. 2014 Mar 14;343(6176):1260-3
pubmed: 24626930
Cancers (Basel). 2020 Jan 23;12(2):
pubmed: 31979293
Leukemia. 2015 Jan;29(1):107-14
pubmed: 24787488
Leuk Res. 2017 Apr;55:41-48
pubmed: 28122282
Oncoimmunology. 2016 Mar 16;5(5):e1132977
pubmed: 27467951
Front Immunol. 2015 Jun 02;6:262
pubmed: 26082779
Front Immunol. 2020 Oct 29;11:593610
pubmed: 33193442
J Immunol. 2016 Sep 1;197(5):1762-75
pubmed: 27474078
Cell Res. 2010 Jan;20(1):34-50
pubmed: 20010915
PLoS One. 2020 Mar 9;15(3):e0230033
pubmed: 32150580
Subcell Biochem. 2017;83:149-183
pubmed: 28271476
Anticancer Agents Med Chem. 2020;20(4):429-436
pubmed: 31823704
Ann Oncol. 2017 Dec 1;28(suppl_12):xii33-xii43
pubmed: 29253115
Blood. 2010 Nov 11;116(19):3705-14
pubmed: 20610811
Blood. 2015 Jul 30;126(5):573-81
pubmed: 26084672
Nat Rev Immunol. 2010 May;10(5):317-27
pubmed: 20414205
J Clin Pathol. 1998 May;51(5):364-9
pubmed: 9708202
Bratisl Lek Listy. 2017;118(11):658-661
pubmed: 29216721
Clin Biochem. 2017 Dec;50(18):1203-1208
pubmed: 28888879
Clin Exp Immunol. 1988 Sep;73(3):484-8
pubmed: 2463123
Cancer Immunol Immunother. 2012 Aug;61(8):1201-10
pubmed: 22215138
Oncologist. 2008 Sep;13(9):954-66
pubmed: 18779537
Proc Natl Acad Sci U S A. 2017 Jan 31;114(5):986-991
pubmed: 28104818
PLoS One. 2019 Jan 2;14(1):e0209024
pubmed: 30601845
Nano Lett. 2019 Jul 10;19(7):4787-4796
pubmed: 31184907

Auteurs

Naseba Naseraldeen (N)

The Institute for Medical Research, Galilee Medical Center, Nahariya, Israel.
Azrieli Faculty of Medicine, Bar Ilan University, Safed, Israel.

Regina Michelis (R)

The Institute for Medical Research, Galilee Medical Center, Nahariya, Israel.

Masad Barhoum (M)

Azrieli Faculty of Medicine, Bar Ilan University, Safed, Israel.
Institute of Hematology, Galilee Medical Center, Nahariya, Israel.

Judith Chezar (J)

Institute of Hematology, Galilee Medical Center, Nahariya, Israel.

Tamar Tadmor (T)

Hematology Unit, Bnai Zion Medical Center, Haifa, Israel.
The Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel.

Ariel Aviv (A)

Department of Hematology, Emek Medical Center, Afula, Israel.

Lev Shvidel (L)

Hematology Institute, Kaplan Medical Center, Rehovot, Israel.
Faculty of Medicine, Hebrew University, Jerusalem, Israel.

Adi Litmanovich (A)

Azrieli Faculty of Medicine, Bar Ilan University, Safed, Israel.

Mona Shehadeh (M)

Biochemistry Laboratory, Galilee Medical Center, Nahariya, Israel.

Galia Stemer (G)

Department of Hematology, Emek Medical Center, Afula, Israel.

Ety Shaoul (E)

Institute of Hematology, Galilee Medical Center, Nahariya, Israel.

Andrei Braester (A)

Azrieli Faculty of Medicine, Bar Ilan University, Safed, Israel.
Institute of Hematology, Galilee Medical Center, Nahariya, Israel.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH